Agency Information Collection Activities; Proposed Collection; Comment Request; Expedited Programs for Serious Conditions-Accelerated Approval of Drugs and Biologics
Published Date: 2/6/2026
Notice
Summary
The FDA wants your thoughts on how it collects info about speeding up drug and biologic approvals for serious illnesses. This affects drug makers and patients waiting for faster access to important treatments. You’ve got until April 7, 2026, to share your comments—so don’t miss out on shaping the future of faster medicine approvals!
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Big Time Burden for Drug Sponsors
If you are a drug or biologic sponsor, FDA estimates new paperwork will take about 400 hours to prepare for each Advisory Committee submission and about 40 hours to prepare a written appeal. FDA estimates two Advisory Committee submissions (800 hours) and one written appeal (40 hours) per year across the Agency, for a total of 3 responses and 840 hours.
Confirmatory Trial & 180-Day Reporting Rule
Under section 3210 of the Consolidated Appropriations Act, FDA may require that confirmatory studies be underway before approval or within a specified time after approval, and sponsors must submit postmarketing reports on the progress of required confirmatory trials approximately every 180 days.
Expanded Protections During Withdrawal Process
If FDA considers withdrawing an accelerated approval, the agency must give the sponsor due notice and an explanation, offer a meeting with the Commissioner or designee, allow a written appeal to an independent designee, provide an advisory committee meeting if requested, and allow public comment with a published summary of comments and FDA's response.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-02385 — Indian Gaming; Approval by Operation of Law of the Sixth Amendment to the Tribal-State Compact for Class III Gaming Between the Lummi Nation and the State of Washington
The Lummi Nation and Washington State’s gaming agreement just got a green light by law on February 6, 2026! This update tweaks some rules, adds new betting limits, and allows electronic wagering, making gaming smoother and more modern. Players and the tribe can now enjoy these changes without delay, boosting fun and fairness on Lummi lands.
Next: 2026-02387 — Determination of Regulatory Review Period for Purposes of Patent Extension; BEQVEZ
The FDA has set the official review period for BEQVEZ, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind BEQVEZ and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s effort during review, you have until early August 2026 to speak up—no money changes hands now, but this could impact how long the patent lasts.